Royal Bank Of Canada Aeterna Zentaris Inc. Transaction History

Royal Bank Of Canada

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.17 - $0.37 $23 - $51	-140 Reduced 98.59%	2 $0
Q1 2022 May 16, 2022	SELL	$0.33 - $0.42 $80 - $102	-243 Reduced 63.12%	142 $0
Q4 2021 Feb 14, 2022	SELL	$0.36 - $0.77 $428 - $917	-1,191 Reduced 75.57%	385 $0
Q3 2021 Nov 15, 2021	BUY	$0.59 - $0.88 $421 - $629	715 Added 83.04%	1,576 $1,000
Q2 2021 Aug 16, 2021	BUY	$0.83 - $1.14 $714 - $981	861 New	861 $1,000

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.